FOOD AND DRUG ADMINISTRATION (FDA)

Center for Drug Evaluation and Research (CDER)

Oncologic Drugs Advisory Committee (ODAC) Meeting October 4, 2023

MEETING ROSTER

ACTING DESIGNATED FEDERAL OFFICER (Non-Voting)

Joyce Frimpong, PharmD

Division of Advisory Committee and Consultant Management Office of Executive Programs, CDER, FDA

ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBERS (Voting)

Mark R. Conaway, PhD

Professor

Division of Translational Research and Applied

Statistics

Department of Public Health Sciences

The University of Virginia School of Medicine

Charlottesville, Virginia

Christopher H. Lieu, MD

(Acting Chairperson)

Associate Professor of Medicine

Associate Director for Clinical Research

Director, Gastrointestinal Medical Oncology Program

University of Colorado

Aurora, Colorado

Jorge J. Nieva, MD

Associate Professor of Clinical Medicine

Section Head, Solid Tumors

University of Southern California (USC) Norris

Comprehensive Cancer Center

Keck School of Medicine of USC

Los Angeles, California

Daniel Spratt, MD

Vincent K Smith Chair, Department of Radiation

Oncology

Professor of Radiation Oncology and Urology University Hospitals Seidman Cancer Center

Case Western Reserve University

Cleveland, Ohio

William J. Gradishar, MD

Professor of Medicine/Betsy Bramsen Professor of

Breast Oncology

Chief, Hematology/Oncology

Robert H. Lurie Comprehensive Cancer Center

Feinberg School of Medicine at Northwestern

University

Chicago, Illinois

David E. Mitchell

(Consumer Representative)

President

Patients for Affordable Drugs

Bethesda, Maryland

Alberto S. Pappo, MD

Member, St. Jude Faculty

Director, Solid Tumor Division

Co-Leader, Developmental Biology & Solid Tumor

Program

Alvin Mauer Endowed Chair

St. Jude Children's Research Hospital

Memphis, Tennessee

Neil Vasan, MD, PhD

Assistant Professor

Division of Hematology & Oncology

Department of Medicine

Herbert Irving Comprehensive Cancer Center

Columbia University Medical Center

New York, New York

FOOD AND DRUG ADMINISTRATION (FDA)

Center for Drug Evaluation and Research (CDER)

Oncologic Drugs Advisory Committee (ODAC) Meeting October 4, 2023

MEETING ROSTER (cont.)

ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBER (Non-Voting)

Jonathan D. Cheng, MD

(Industry Representative)
Senior Vice President
Head of Oncology Development
Global Drug Development
Bristol-Myers Squibb
Lawrenceville, New Jersey

TEMPORARY MEMBERS (Voting)

G. Caleb Alexander, MD, MS

Professor of Epidemiology and Medicine Center for Drug Safety and Effectiveness Johns Hopkins Bloomberg School of Public Health Baltimore, Maryland

Mary Ellen Cosenza, PhD, DABT

Consultant MEC Regulatory & Toxicology Consulting, LLC Moorpark, California

Gianna McMillan, DBE, MFA

(Patient Representative) Los Angeles, California

Pamela Shaw, PhD, MS

Senior Investigator Biostatistics Division Kaiser Permanente Washington Health Research Institute Seattle, Washington

Shahab Asgharzadeh, MD

Associate Professor of Pediatrics Director, Neuroblastoma Basic and Translational Program Children's Hospital Los Angeles University of Southern California Los Angeles, California

AeRang Kim, MD, PhD

Director of Clinical Research Division of Oncology Children's National Hospital Associate Professor of Pediatrics The George Washington School of Medicine Washington, District of Columbia

Donald Williams (Will) Parsons, MD, PhD

Deputy Director Texas Children's Cancer and Hematology Center Professor of Pediatrics Baylor College of Medicine Houston, Texas

Til Stürmer, MD, MPH, PhD

Nancy A. Dreyer Distinguished Professor and Chair Department of Epidemiology Gillings School of Global Public Health University of North Carolina at Chapel Hill Chapel Hill, North Carolina

FOOD AND DRUG ADMINISTRATION (FDA)

Center for Drug Evaluation and Research (CDER)

Oncologic Drugs Advisory Committee (ODAC) Meeting October 4, 2023

MEETING ROSTER (cont.)

TEMPORARY MEMBERS (Voting) (cont.)

Clare J. Twist, MD

Professor of Oncology

The Katie Dougherty Endowed Chair in Pediatric Oncology

Director, Pediatric Developmental Therapeutics Roswell Park Comprehensive Cancer Center Oishei Children's Hospital

Buffalo, New York

Brian Weiss, MD

Professor of Pediatrics Chief, Division of Pediatrics Hematology/Oncology/Stem Cell Transplant Riley Hospital for Children Indiana University Indianapolis, Indiana

FDA PARTICIPANTS (Non-Voting)

Richard Pazdur, MD

Director, Oncology Center of Excellence (OCE)
Office of the Commissioner (OC)
Director (Acting)
Office of Oncologic Diseases (OOD)
Office of New Drugs (OND), CDER, FDA

Martha Donoghue, MD

Associate Director for Pediatric Oncology OCE, OC, OOD, OND, CDER, FDA

Diana Bradford, MD

Cross Disciplinary Team Leader DO2, OOD, OND, CDER, FDA

Arup Sinha, PhD

Statistics Reviewer
Division of Biometrics V
Office of Biostatistics
Office of Translational Sciences, CDER, FDA

Yoram Unguru, MD, MS, MA, HEC-C

Attending Physician

Division of Pediatric Hematology/Oncology The Herman & Walter Samuelson Children's

Hospital at Sinai

Chairman, Sinai Hospital Ethics Committee Core Faculty, Johns Hopkins Berman Institute of Bioethics

Associate Professor, Johns Hopkins University School of Medicine Baltimore, Maryland

Brigitte Widemann, MD

Senior Investigator Chief, Pediatric Oncology Branch National Cancer Institute National Institutes of Health Bethesda, Maryland

Paul Kluetz, MD

Deputy Center Director OCE, OC Supervisory Associate Director (Acting) OOD, OND, CDER, FDA

Nicole Drezner, MD

Deputy Division Director Division of Oncology 2 (DO2) OOD, OND, CDER, FDA

Elizabeth S. Duke, MD

Clinical Reviewer DO2, OOD, OND, CDER, FDA

Emily Wearne, PhD

Nonclinical Reviewer Division of Hematology Oncology Toxicology OOD, OND, CDER, FDA